Omentin-1 vs Lixisenatide
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Lixisenatide |
|---|---|---|
| Category | Diabetes & Metabolic | Weight Management |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Exendin-4-derived GLP-1 receptor agonist |
| Molecular Weight | ~35 kDa | 4858 Da |
| Half-Life | hours | 2-4 hours |
| Amino Acids | 313 | 44 |
| Typical Dose | No approved human dose; research use only | 10-20 mcg daily |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 400 |
| Research Status | Pre-clinical | Approved |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Lixisenatide Benefits
- ✓postprandial glucose control
- ✓modest weight loss
- ✓appetite reduction
- ✓short-acting option
Omentin-1 Dosing
not established|not established
Lixisenatide Dosing
10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Lixisenatide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠hypoglycemia when combined with insulin
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Lixisenatide
Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.